Article

Biosyntrx introduces portion-control capsule

Biosyntrx Corp. is partnering with Wellosophy Corp. to include a professional-strength version of a proprietary hydrogel gastric bulking technology (Swell) into Biosyntrx's new mealtime portion-control product (Avantrx).

Key Points

Lexington, SC, and Colorado Springs, CO-Biosyntrx Corp. is partnering with Wellosophy Corp. to include a professional-strength version of a proprietary hydrogel gastric bulking technology (Swell) into Biosyntrx's new mealtime portion-control product (Avantrx). The new formula will be delivered in a certified kosher and bovine spongiform encephalopathy-free, two-piece gelatin capsule containing 750-mg microbeads, according to the companies.

"We have identified more than 50 peer-reviewed studies that suggest a direct correlation between excess weight and an increased risk for each of the four major vision-loss or blinding diseases: cataracts, glaucoma, diabetic retinopathy, and age-related macular degeneration," said Ellen Troyer, Biosyntrx executive vice president and chief research officer.

The proprietary gastric bulking agent was invented by Richard C. Davis, MD, the founder, chief executive officer, and chief scientific officer of several companies, including the publicly traded OccuLogix Inc. and UroQuest Medical Corp.

When a capsule is taken 45 to 60 minutes before a meal with an 8- to 12-ounce glass of room-temperature water, the hundreds of microbeads within the capsule collectively expand within minutes to fill a volume the size of a large apple, according to the companies. The microbeads are retained in the stomach for 2 to 3 hours then pass through the gastrointestinal tract and are eliminated naturally.

The technology recently was evaluated in a multicenter clinical trial that included 30 overweight volunteers at four physician-managed weight-loss clinics. Although not definitive, the study found that participants were able to reduce meal portions by an average of 34% and had progressive weight loss averaging 7.6 pounds over the 4-week study period; no significant side effects were reported, according to the companies.

Additional studies are being planned to evaluate the safety and efficacy of the product in adolescent children and in adults with type 2 diabetes.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.